MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, ...
Veru and its shareholders had high hopes for sabizabulin, an orally administered COVID treatment. These hopes were diminished greatly on Wednesday, when a Food and Drug Administration (FDA) advisory ...
Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development ...
-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- As part ...
Veru Inc. (VERU) is a great speculative biotech play to look into, despite a rejection by the FDA of the Emergency Use Authorization (EUA) of Sabizabulin for the treatment of patients with moderate to ...
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, both dates ...
MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Image source: The Motley Fool. Veru (NASDAQ:VERU) presented new regulatory feedback confirming potential U.S. approval paths for Novosarm-GLP-1 combination therapy based on either incremental weight ...
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Veru Inc. (NASDAQ: VERU) common stock between May 11, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results